Paschen A, Arens N, Sucker A, Greulich-Bode KM, Fonsatti E, Gloghini A, Striegel S, Schwinn N, Carbone A, Hildenbrand R, Cerwenka A, Maio M, Schadendorf D.
(2006) The coincidence of chromosome 15 aberrations and beta2-microglobulin gene mutations is causative for the total loss of human leukocyte antigen class I expression in melanoma.
Clin Cancer Res. 12(11 Pt 1):3297-305.

Thirumaran RK, Thoelke A, Ugurel S, Hemminki K, Schadendorf D, Kumar R.
(2006). Association between Endothelin Receptor B nonsynonymous variants and melanoma risk.
J Nat Cancer Institute, in press.

Thoelke A, Thirumaran RK, Ugurel S, Gast A, Hemminki K, Kumar R, Schadendorf D.
(2006). Multiple melanomas in a non-Dutch p16-Leiden mutation carrier with two MC1R high-risk variants after treatment for Hodgkin’s Lymphoma.
Arch Dermatol, in revison.

Müller-Berghaus J, Ehlert K, Ugurel S, Umansky V, Bucur M, Schirrmacher V, Beckhove P, Schadendorf D.
(2006). Melanoma-reactive T cells in the bone marrow of melanoma patients: Association with disease stage and disease duration.
Cancer Res Jun 15;66(12):5997-6001.

Mian S.*, Ugurel S.*, Parkinson E., Ball G., Creaser C., Rees R. and Schadendorf D.
(2005). Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients.
J Clin Oncol 23(22):5088-93. *equal contribution.

Paschen A, Song M, Osen W, Nguyen X D, Mueller-Berghaus J, Fink D, Daniel N, Donzeau M, Nagel W, Kropshofer H, Schadendorf D.
(2005). Detection of spontaneous CD4+ T-cell responses in Melanoma patients against a Tyrosinase-related protein-2 – Derived epitope identified in HLA-DRB1 *0301 transgenic mice.
Clin Cancer Res 2005; 11 (14): 5241-5247.